Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

834 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Raised blood pressure and risk of dementia.
Gregson J, Qizilbash N, Pocock S. Gregson J, et al. Among authors: pocock s. Eur Heart J. 2019 Mar 1;40(9):785-786. doi: 10.1093/eurheartj/ehy912. Eur Heart J. 2019. PMID: 30689820 No abstract available.
Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction.
Rossignol P, Duarte K, Girerd N, Karoui M, McMurray JJV, Swedberg K, van Veldhuisen DJ, Pocock S, Dickstein K, Zannad F, Pitt B. Rossignol P, et al. Among authors: pocock s. Eur J Heart Fail. 2020 Aug;22(8):1402-1411. doi: 10.1002/ejhf.1724. Epub 2020 Jan 9. Eur J Heart Fail. 2020. PMID: 31919958 Free article.
Use of the Win Ratio in Cardiovascular Trials.
Ferreira JP, Jhund PS, Duarte K, Claggett BL, Solomon SD, Pocock S, Petrie MC, Zannad F, McMurray JJV. Ferreira JP, et al. Among authors: pocock s. JACC Heart Fail. 2020 Jun;8(6):441-450. doi: 10.1016/j.jchf.2020.02.010. JACC Heart Fail. 2020. PMID: 32466836 Free article.
Timing of Statistical Benefit of Mineralocorticoid Receptor Antagonists Among Patients With Heart Failure and Post-Myocardial Infarction.
Bedrouni W, Sharma A, Pitt B, Lam CSP, Ni J, Ferreira JP, McMurray J, Giannetti N, Girerd N, Rossignol P, Solomon SD, Claggett B, Pocock S, Huynh T, Zannad F. Bedrouni W, et al. Among authors: pocock s. Circ Heart Fail. 2022 Oct;15(10):e009295. doi: 10.1161/CIRCHEARTFAILURE.121.009295. Epub 2022 Aug 4. Circ Heart Fail. 2022. PMID: 35924555 Free article. No abstract available.
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.
Verma S, Dhingra NK, Butler J, Anker SD, Ferreira JP, Filippatos G, Januzzi JL, Lam CSP, Sattar N, Peil B, Nordaby M, Brueckmann M, Pocock SJ, Zannad F, Packer M; EMPEROR-Reduced trial committees and investigators. Verma S, et al. Among authors: pocock sj. Lancet Diabetes Endocrinol. 2022 Jan;10(1):35-45. doi: 10.1016/S2213-8587(21)00292-8. Epub 2021 Nov 30. Lancet Diabetes Endocrinol. 2022. PMID: 34861154
J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individual-patient data.
Boutitie F, Gueyffier F, Pocock S, Fagard R, Boissel JP; INDANA Project Steering Committee. INdividual Data ANalysis of Antihypertensive intervention. Boutitie F, et al. Among authors: pocock s. Ann Intern Med. 2002 Mar 19;136(6):438-48. doi: 10.7326/0003-4819-136-6-200203190-00007. Ann Intern Med. 2002. PMID: 11900496
834 results